During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

See below to download the Meeting Impression This lunch symposium held during ESC Heart Failure 2017 explored mechanisms and common pathways underlying the development of cardiovascular disease (CVD) and heart failure (HF) and the particular risk of patients with diabetes. Innovation in the field of HF management is ongoing. This has yielded several new agents in recent years, which are likely to change clinical practice. The role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, was discussed in the context of a risk-based intervention strategy that targets glucose control and CV risk factors.

• Adriaan Voors, MD, UMCG, Groningen, The Netherlands
• Prof. Martin Cowie, Imperial College London, London, United Kingdom
• Prof. Per-Henrik Groop, University of Helsinki, Helsinki, Finland
• Prof. John McMurray, University of Glasgow, United Kingdom

Funding

This satellite symposium was organised by the PACE Foundation and sponsored by an unrestricted educational grant of Boehringer Ingelheim/Lilly.

Download Meeting Impression View lecture - Challenges in Heart Failure management: Diabetes and Renal Impairment - by Prof. Martin Cowie View lecture - SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome - by Prof. Per Henrik Groop